Research
Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $111.20, according to analysts polled by FactSet.
$ARWR
$ARWR
17 stories mentioning ARWRUpdated 16d ago
Every FINWIRES story that references ARWR, newest first.
What are analysts saying about ARWR?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on ARWR?
Wire
Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says
Arrowhead Pharmaceuticals (ARWR) thinks Plozasiran could receive US Food and Drug Administration approval to treat severe hypertriglyceridemia, or sHTG, by the second quarter of 2027, RBC Capital Markets analysts said in a Sunday note.Arrowhead expects to file a supplemental new drug application for the therapy with the FDA before the end of 2026, the analysts said.On the commercial side, the company noted that educating physicians and activating patients is key, and that the market is relatively concentrated, the analysts said.Outside the United States, the company is planning to rely on local distributors, except for China, where Sanofi (SNY) has the rights to the molecule, RBC said.Analysts said that while Arrowhead shares have risen about eightfold since April 2025, the company is poised to successfully transition from a science organization to a "commercial powerhouse."RBC has an outperform rating and a $100 price target on the stock, with a speculative-risk designation.Price: $81.59, Change: $-3.33, Percent Change: -3.92%
$ARWR$SNY
Sectors
Sector Update: Healthcare Stocks Fall Premarket Monday
Healthcare stocks were falling premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) down 0.6%.Arrowhead Pharmaceuticals' (ARWR) plozasiran met its primary and secondary endpoints in two phase 3 studies as a potential treatment for adults with severe hypertriglyceridemia, the company said. Shares of Arrowhead Pharmaceuticals were down more than 2% pre-bell.Hutchmed (HCM) shares were up more than 2% after the company said its experimental combination of Orpathys and Tagrisso demonstrated a statistically significant improvement in progression-free survival in a China phase 3 trial involving certain patients with non-small cell lung cancer.IDEAYA Biosciences (IDYA) stock was 0.7% higher after the company said it held a US Food and Drug Administration meeting on the design of a phase 3 trial for IDE849, its experimental treatment for extensive-stage small cell lung cancer.
$ARWR$HCM$IBB$IDYA$XLV
Sectors
Sector Update: Healthcare
Healthcare stocks were falling premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) down 0.6%.Arrowhead Pharmaceuticals' (ARWR) plozasiran met its primary and secondary endpoints in two phase 3 studies as a potential treatment for adults with severe hypertriglyceridemia, the company said. Shares of Arrowhead Pharmaceuticals were down more than 2% pre-bell.
$ARWR
Insider Trading
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,012,680, According to a Recent SEC Filing
Michael S Perry, Director, on August 18, 2026, sold 11,600 shares in Arrowhead Pharmaceuticals (ARWR) for $1,012,680. Following the Form 4 filing with the SEC, Perry has control over a total of 111,459 common shares of the company, with 111,459 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/879407/000125037926000002/xslF345X05/wk-form4_1787260939.xml
$ARWR
Wire
Arrowhead Pharmaceuticals' Redemplo Now Available in Germany for FCS Patients
Arrowhead Pharmaceuticals (ARWR) said Monday that Redemplo is now available in Germany to treat adults with Familial Chylomicronaemia Syndrome (FCS), or dangerously high levels of triglycerides in the bloodstream.Following its marketing authorization by the European Commission in June, Redemplo is now listed in the Lauer-Taxe database and thus able to be prescribed, dispensed and reimbursed in Germany, the company said.Arrowhead shares were 1.1% higher in Monday trading.Price: $87.26, Change: $+0.61, Percent Change: +0.71%
$ARWR
Wire
B. Riley Adjusts Arrowhead Pharmaceuticals Price Target to $123 From $101, Maintains Buy Rating
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $105.40, according to analysts polled by FactSet.Price: $87.58, Change: $+1.36, Percent Change: +1.58%
$ARWR
Sectors
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Repligen (RGEN) has agreed to acquire BioLife Solutions (BLFS) in a deal valued at about $1.5 billion, the companies said. Repligen shares climbed 2.3%, and BioLife jumped past 6%.Amgen (AMGN) has agreed to pay $74 million to settle a shareholder lawsuit alleging the company waited too long to disclose it may owe the Internal Revenue Service $10.7 billion in back taxes, penalties and interest, news outlets reported Tuesday. Amgen shares were down 0.1%.Arrowhead Pharmaceuticals (ARWR) shares surged past 20% after the company said its phase 3 clinical studies of plozasiran to treat hypertriglyceridemia met the primary endpoint of triglyceride reduction compared with placebo.GSK (GSK) shares were fractionally higher after it said Wednesday the US Food and Drug Administration has approved Jideytro, a ROS1-selective inhibitor, to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor.
$AMGN$ARWR$BLFS$GSK$RGEN
Sectors
Sector Update: Healthcare
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Arrowhead Pharmaceuticals (ARWR) shares jumped past 21% after the company said its phase 3 clinical studies of plozasiran to treat hypertriglyceridemia met the primary endpoint of triglyceride reduction compared with placebo.
$ARWR
Wire
Arrowhead Pharmaceuticals Shares Rise After Phase 3 Trials of Plozasiran Meets Primary, Secondary Endpoints
Arrowhead Pharmaceuticals (ARWR) shares rose 22.1% on Wednesday after the company said its phase 3 clinical studies of plozasiran to treat hypertriglyceridemia met the primary endpoint of triglyceride reduction compared with placebo.Studies also met all secondary endpoints, including a statistically significant reduction in the rate of acute pancreatitis compared with placebo, according to a statement.The 25 mg dosage administered subcutaneously once every three months led to median triglyceride reductions of 79% and 81%, respectively, at month 12, the company said.The drug candidate demonstrated a favorable safety and tolerability profile, with treatment emergent adverse events consistent with its established safety profile, the company said.The company will utilize phase 3 trial data to apply for marketing authorization for sHTG in multiple global geographies, beginning with a planned supplemental new drug application with the US FDA before 2026-end, according to the company.Price: $90.87, Change: $+16.35, Percent Change: +21.94%
$ARWR
Wire
Top Midday Gainers
Arrowhead Pharmaceuticals (ARWR) said Wednesday topline results from its global phase 3 clinical studies of plozasiran in patients with severe hypertriglyceridemia showed the trials "successfully met" primary endpoint of triglyceride reduction versus placebo and met all prespecified secondary endpoints in both studies.Shares surged 24% amid an increase in intraday trading volume to over 4.8 million from a daily average of roughly 2.1 million.Super Micro Computer (SMCI) soared 22% amid heavy trading after the company said it expects fiscal Q4 GAAP and non-GAAP gross margins in the range of 15% to 17%, significantly above its 8.2% to 8.4% forecast on the back of a favorable customer and product mix, according to a statement late Tuesday.Over 126 million shares traded intraday versus a daily average of roughly 51.4 million.First Financial Bancorp (FFBC) agreed to acquire Finward Bancorp (FNWD) for about $208 million in stock to expand in northwest Indiana and Chicago, according to a statement late Tuesday.Shares jumped 22%, with intraday trading volume rising to more than 126,900 from the stock's daily average of about 17,000.Price: $31.31, Change: $+5.81, Percent Change: +22.79%
$ARWR$FNWD$SMCI
Research
Stifel Initiates Arrowhead Pharmaceuticals at Buy With $98 Price Target
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $91.82, according to analysts polled by FactSet.
$ARWR
Wire
Arrowhead Reports Marketing Authorization for Redemplo in EU
Arrowhead Pharmaceuticals (ARWR) said Monday the European Commission has granted marketing authorization for Redemplo as an adjunct to diet to reduce triglyceride levels in adults with familial chylomicronemia syndrome.The approval was supported by positive phase 3 Palisade trial data, the company said.Shares were up over 1% in afternoon trading.Price: $82.98, Change: $+1.16, Percent Change: +1.42%
$ARWR
Wire
RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $85.09, according to analysts polled by FactSet.Price: $73.94, Change: $-4.01, Percent Change: -5.14%
$ARWR
Wire
Arrowhead Signs Deal With Madrigal to License Clinical MASH Program
Arrowhead Pharmaceuticals (ARWR) said Tuesday it has signed an agreement with Madrigal Pharmaceuticals (MDGL) to exclusively license its ARO-PNPLA3 program, which is evaluating a potential treatment for metabolic dysfunction-associated steatohepatitis, or MASH.Under the agreement, Arrowhead said that Madrigal will receive a global license to develop, manufacture, and commercialize ARO-PNPLA3, which uses the TRiM platform to silence hepatocyte expression of patatin-like phospholipase domain-containing 3, or PNPLA3, as a potential treatment for patients with MASH.When the deal closes, Arrowhead said it will receive a $25 million upfront payment and be eligible to receive up to an additional $975 million upon meeting development, regulatory, and sales milestones.Arrowhead said it is also eligible to receive tiered royalties on commercial sales ranging from high single digits to the mid-teens.Price: $76.58, Change: $+0.19, Percent Change: +0.25%
$ARWR$MDGL
Research
JPMorgan Initiates Arrowhead Pharmaceuticals at Overweight With $88 Price Target
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $85.09, according to analysts polled by FactSet.
$ARWR
Research
Morgan Stanley Upgrades Arrowhead Pharmaceuticals to Overweight From Equal Weight, Adjusts PT to $100 From $78
Arrowhead Pharmaceuticals (ARWR) has an average rating of Buy and mean price target of $84.80, according to analysts polled by FactSet.
$ARWR
